BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Cancers (Basel) 2020;12:E3051. [PMID: 33092063 DOI: 10.3390/cancers12103051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hu M, Ekshyyan O, Herman Ferdinandez L, Rong X, Caldito G, Nathan CO. Efficacy and comparative effectiveness of sirolimus as an anticancer drug. Laryngoscope 2011;121:978-82. [PMID: 21520111 DOI: 10.1002/lary.21724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]